All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Voruciclib With or Without Venetoclax Shows Safety, Activity in R/R AML, B-cell Malignancies

May 24th 2023

Voruciclib monotherapy and in combination with venetoclax demonstrated clinical activity and was well tolerated with no significant myelosuppression in heavily pretreated patients with relapsed/refractory acute myeloid leukemia or B-cell malignancies, according to initial data from a phase 1 trial.

NCCN Guidelines List Ropeginterferon Alfa-2b as Preferred Treatment in Polycythemia Vera

May 24th 2023

The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been revised to include ropeginterferon alfa-2b-njft as a preferred treatment option for patients with high- and low-risk polycythemia vera, irrespective of treatment history.

Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

May 24th 2023

CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.

Milademetan Plus ONC201 Could Represent Synergistic Combination in MDM2-overexpressing Solid Tumors

May 24th 2023

Ilyas Sahin, MD, details the preclinical findings from the study and highlighted how these data could help inform future studies for the treatment of patients with MDM2-overexpressing solid tumors.

Ribociclib/Fulvestrant Combo Generates PFS Improvement in Metastatic Breast Cancer

May 23rd 2023

Ribociclib plus switch endocrine therapy induced a statistically significant progression-free survival benefit compared with placebo plus switch endocrine therapy in patients with hormone receptor–positive, HER2-negative, metastatic breast cancer.

China’s NMPA Accepts sNDA for Toripalimab Plus Chemo in Advanced TNBC

May 23rd 2023

The National Medical Products Administration has accepted the supplemental new drug application seeking the approval of toripalimab in combination with nab-paclitaxel in patients with untreated metastatic or recurrent triple-negative breast cancer and a PD-L1 combined positive score of at least 1.

SPEECH Conference Highlights Multiplicity of Ongoing Efforts in Cancer Care Equity

May 23rd 2023

Young investigators, fellows, and medical students recently gathered at the Temple University Lewis Katz School of Medicine in Philadelphia, Pennsylvania, to network and share exciting research aimed at addressing disparities in the dissemination of cancer care at the 5th Annual Regional Synergistic Partnership for Enhancing Equity in Cancer Health Conference and Retreat.

Sintilimab/Axitinib Combo Shrinks FH-Deficient RCC Tumors

May 23rd 2023

Xingming Zhang, MD, discusses unmet needs in fumarate hydratase–deficient renal cell carcinoma; shares key efficacy, safety, and quality of life findings from a phase 2 trial of sintilimab plus axitinib; and elaborates on the next steps for this research, including an analysis of biomarkers and potential resistance mechanisms.

Northwestern Medicine Successfully Performs Double-lung Transplant on a Second Patient With Stage 4 Lung Cancer and Launches First-of-its-kind Clinical Program

May 23rd 2023

For the second time at Northwestern Medicine, surgeons have successfully performed a double-lung transplant on a patient with stage 4 lung cancer who was being considered for hospice.

FDA Grants Priority Review to Lumisight Optical Imaging Agent for Breast Cancer Detection

May 23rd 2023

The FDA has granted priority review to a new drug application seeking the approval of the optical imaging agent Lumisight for use in patients with breast cancer, according to an announcement from Lumicell, Inc.

Health-Related QOL Differences Are Observed for Young Adults With CRC

May 23rd 2023

Amanda Bloomer, PhD, highlights the growing need for more research for this growing patient population and the age-specific findings that were seen in the ColoCare trial.

Advances Across Urothelial Carcinomas Highlight Need for Shared Decision-making

May 23rd 2023

As longer-term data read out for established regimens in urothelial cancer and up-and-coming therapeutics inch toward approval, optimizing treatment approaches relies on buy-in from multidisciplinary teams and patients.

NICE Recommends Pembrolizumab Plus Lenvatinib for Previously Treated Advanced or Recurrent Endometrial Cancer

May 22nd 2023

The National Institute for Health and Care Excellence has recommended the combination of pembrolizumab and lenvatinib for use in previously treated patients with advanced or recurrent endometrial cancer whose cancer has progressed on or after platinum-based chemotherapy and who cannot have curative surgery or radiotherapy.

FDA Approves Avapritinib for Indolent Systemic Mastocytosis

May 22nd 2023

The FDA has approved avapritinib (Ayvakit) for the treatment of adults with indolent systemic mastocytosis.

Investigation of CAR T-cell Therapy in Earlier Treatment Lines Could Continue to Alter Treatment Sequencing in Myeloma

May 22nd 2023

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

FDA Grants Orphan Drug Designation to Mitazalimab in Pancreatic Cancer

May 22nd 2023

The FDA has granted an orphan drug designation to mitazalimab for use as a potential therapeutic option in patients with pancreatic cancer.

GEN-002 Plus Avelumab Shows Promise as Third-line Option in PD-L1+ Gastric Cancer

May 22nd 2023

The combination of GEN-002 and avelumab elicited responses in patients with advanced gastric or gastroesophageal junction adenocarcinoma, according to findings from an interim analysis of an ongoing phase 2 trial.

Milademetan Fails to Meet PFS End Point in Dedifferentiated Liposarcoma

May 22nd 2023

Treatment with milademetan did not lead to a statistically significant improvement in progression-free survival compared with trabectedin in patients with dedifferentiated liposarcoma, failing to reach the primary end point of the phase 3 MANTRA trial.

OncLive Honors 12 Cancer Care Pioneers

May 22nd 2023

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Dana-Farber Researchers Report on the Safety and Activity of Immune Checkpoint Inhibitors in People Living with HIV and Cancer

May 22nd 2023

People living with HIV remain at higher risk than people living without HIV for developing various cancers that can be treated with immune checkpoint inhibitors.